{"id":1783,"date":"2008-12-01T12:07:00","date_gmt":"2008-12-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/tibolon-studie-bei-aelteren-frauen-wegen-haeufigerer-schlaganfaelle-abgebrochen"},"modified":"2008-12-01T12:07:00","modified_gmt":"2008-12-01T11:07:00","slug":"tibolon-studie-bei-aelteren-frauen-wegen-haeufigerer-schlaganfaelle-abgebrochen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/tibolon-studie-bei-aelteren-frauen-wegen-haeufigerer-schlaganfaelle-abgebrochen","title":{"rendered":"Tibolon-Studie bei \u00e4lteren Frauen wegen h\u00e4ufigerer Schlaganf\u00e4lle abgebrochen"},"content":{"rendered":"<p>Tibolon (T; Liviella\u00ae) ist ein sogenannter \u201eSelective tissue estrogenic activity regulator\u201d (STEAR). Es ist in einer Tagesdosis von 2,5 mg in vielen L\u00e4ndern, aber nicht in den USA, f\u00fcr die Behandlung von Hitzewallungen in der Peri-\/Post-Menopause zugelassen. T hat \u00f6strogene, androgene und gestagene Eigenschaften. Es kann den postmenopausalen Verlust an Knochenmineralien vermindern (1). Das veranlasste [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tibolon (T; Liviella\u00ae) ist ein sogenannter \u201eSelective tissue estrogenic activity regulator\u201d (STEAR). Es ist in einer Tagesdosis von 2,5 mg in vielen L\u00e4ndern, aber nicht in den USA, f\u00fcr die Behandlung von Hitzewallungen in der Peri-\/Post-Menopause zugelassen. T hat \u00f6strogene, androgene und gestagene Eigenschaften. Es kann den postmenopausalen Verlust an Knochenmineralien vermindern (1). Das veranlasste [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3964,70,3963],"class_list":["post-1783","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-lift-studie","tag-osteoporose","tag-tibolon"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1783"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1783\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}